Study validating economic advantages of PTRA test

Verici Dx PLC

02 June 2026

 

Verici Dx plc

("Verici Dx" or the "Company")

Study validating economic advantages of PTRA test published

Verici Dx Plc, (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces the publication of a health economic cost impact analysis demonstrating the significant potential cost benefit of the Pre-Transplant Risk Assessment ("PTRA") test for predicting early acute rejection ("EAR") in kidney transplant. The study, titled 'Cost Impact of a Novel Pre-transplant Risk Assessment Tool for Early Acute Rejection in Kidney Transplant Patients' was conducted by Avalon Health Economics and has been published in the Journal of Health Economics and Outcomes Research. The PTRA test is commercially marketed by Thermo Fisher Scientific*.

The study shows that integrating PTRA™ into standard clinical practice could generate substantial healthcare savings while also supporting more personalised immunosuppression strategies for patients. Key findings of the study include the potential for more than $191 million in healthcare savings across the U.S. standard-risk kidney transplant population over two years.

The authors also note that more intense immunosuppression is often used in patients without clear low risk patient characteris-tics. Based on their study, the authors conclude that incorporating the PTRA test in standard-of-care protocols may allow clinicians to more confidently tailor immunosuppression at a reduced level, reducing medication-related adverse events and unfavourable clinical outcomes. The approach may also allow for more intense immunosuppression for some patients with a high-risk PTRA result, reducing acute rejection and its subsequent effects.

*The Pre-Transplant Risk Assessment (PTRA) test is a laboratory developed test, and its performance characteristics determined by the CLIA laboratory performing the test. It has not been cleared or approved by the U.S. Food and Drug Administration or CE marked in the EU.

Beatrice Concepcion, MD, Medical Director, Kidney and Pancreas Transplant, University of Chicago Medicine said: "Early acute rejection remains one of the most significant drivers of post-transplant complications, graft injury, and healthcare costs. Having the ability to stratify rejection risk before transplantation could meaningfully change how we approach immunosuppression. The PTRA test has the potential to help clinicians personalize therapy, escalating treatment for patients who truly need it while avoiding unnecessary exposure in lower-risk patients."

Sara Barrington, Chief Executive Officer of Verici Dx, said: "Kidney transplant recipients require carefully managed immunosuppressive therapy to prevent rejection while minimizing complications due to immunosuppression associated infections, adverse drug events, or malignancies. However, clinicians currently lack robust tools to accurately stratify patient risk for early rejection prior to transplantation. This publication highlights the substantial value that a precision diagnostic like PTRA can bring to transplant medicine, supporting more informed clinical decisions, improving patient management, and potentially saving the healthcare system millions of dollars."

Verici Dx plc	www.vericidx.com
Sara Barrington, CEO	Via Walbrook PR
Singer Capital Markets (Nominated adviser, Joint Broker)		Tel: [phone]
Alex Bond / Russell Cook / Jalini Kalaravy
Oberon Capital (Joint Broker)	Tel: [phone]
Mike Seabrook / Adam Pollock
Walbrook PR (Media & Investor Relations)	Tel: [phone] or [e-mail]
Alice Woodings / Rachel Broad	Mob: [phone]

Verici Dx

Verici Dx plc (AIM: VRCI) is a precision diagnostics company transforming care for transplant patients. The company combines multiomic analysis with proprietary artificial intelligence to deliver predictive, actionable, data-driven intelligence that reflects the complexity and heterogeneity of transplant patients, enabling clinicians to optimise therapy, guide biopsy decisions, and stratify risk with greater confidence.

Operating at the intersection of laboratory and data science, Verici Dx develops complex models that answer the clinical questions that matter most with unrivaled clarity and precision. All tests are built to rigorous scientific standards, validated across inclusive, and real-world patient populations to ensure clinical relevance and reliability. Verici Dx's lead product, Tutivia™, is a post-kidney transplant test focused on early detection of acute rejection.

The company is UK headquartered in Cardiff for the UK, and in Franklin, Tennessee for the U.S. For more information, please visit https://vericidx.com/ and follow us on LinkedIn.

 

 

END